Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 6/20 | 0.41 |
| ▸ | KDM1A | O60341 | 5/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5348213 | 0.90 | PIM2 (0.39) | PIM2PIM3FLT3MAPK8PIM1 | |
| SCHEMBL5354502 | 0.90 | MAPK8 (0.39) | PIM2PIM3MAPK8CNR2PIM1 | |
| SCHEMBL5343142 | 0.89 | PIM3 (0.41) | EP300KDM1APIM2PIM3FLT3 | |
| SCHEMBL5348294 | 0.86 | CDK5 (0.47) | EP300KDM1APIM2PIM3FLT3 | |
| SCHEMBL5346073 | 0.85 | CDK5 (0.54) | EP300KDM1APIM2PIM3FLT3 | |
| SCHEMBL5354930 | 0.81 | KDM4E (0.41) | CNR2 | |
| SCHEMBL5348280 | 0.80 | CDK5 (0.53) | PIM2PIM3FLT3PIM1 | |
| SCHEMBL5348983 | 0.79 | CDK5 (0.40) | PIM2MAPK8PIM1 | |
| SCHEMBL14558859 | 0.79 | CHRNB2 (0.42) | — | |
| SCHEMBL5349163 | 0.79 | BTK (0.39) | PIM2FLT3MAPK8PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483263-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2004-12-08 | — | — | EP | claimed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | claimed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | claimed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | claimed |
| WO-2003070727-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2003-08-28 | — | — | WO | claimed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | claimed |
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1483263-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | disclosed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | disclosed |
| WO-2003070727-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | EP300 3893/4885KDM1A 2930/4885PIM2 1243/4885 |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | EP300 3893/4885KDM1A 2930/4885PIM2 1243/4885 |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | EP300 3893/4885KDM1A 2930/4885PIM2 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.